Skip to main content

Nolvadex (Tamoxifen) an Antioestrogen of Potential Use in the Management of Carcinoma of the Prostate

  • Chapter
  • 73 Accesses

Part of the book series: NATO Advanced Science Institutes Series ((NSSA,volume 53))

Abstract

Well-differentiated prostatic cancer cells, like normal prostatic cells, remain for a time, androgen-dependent. Oestrogens in sufficient dosage reduce circulating androgens, and this has been the rationale for conventional oestrogen therapy. At least 3 mg. daily of Stilboestrol, in divided doses, are needed to suppress plasma testosterone levels throughout 24 hours (1,2), but clinically 1 mg. per day is as effective in controlling the disease (3). This therapeutic evidence for an additional direct action of oestrogens upon the prostate is supported by the classical animal experiments of Huggins and Clark in 1940 (4) and by the tissue culture studies of Earnsworth (5).

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. M.R.G. Robinson and B.G. Thomas, Effect of Hormone Therapy and Plasma Testosterone Levels in Prostatic Cancer, B.M.J. 4:391 (1971).

    Article  CAS  Google Scholar 

  2. R.J. Shearer, W.F. Hendry, I.F. Sommeryille and J.D. Fergusson, Plasma Testosterone: An Accurate Monitor of Hormone Treatment in Prostatic Cancer, Brit. J. Urol. 45:668 (1973).

    Article  PubMed  CAS  Google Scholar 

  3. D.P. Byar, The Veterans Administrators Co-operative Urological Group’s Studies of Cancer of the Prostate: A Preliminary Report, Cancer 32:1126 (1973).

    Article  PubMed  CAS  Google Scholar 

  4. C. Huggins and P.J. Clark, The Effects of Castration and Estrogen Injections on the Normal and Hyperplastic Prostate Gland of Dogs, J. Exp. Med. 72:747 (1941).

    Article  Google Scholar 

  5. W.E. Farnsworth, The Normal Prostate and Its Endocrine Control, in “The Third Tenovus Workshop — Some Aspects of the Aetiology and Biochemistry of Prostatic Cancer”, K. Griffith and C.G. Pierrpoint (eds), Alpha Omega Ltd., Cardiff (1970) p. 3.

    Google Scholar 

  6. E.F. Hawkins et al, Steroid Receptors in the Human Prostate, Steroids, 26:458 (1975).

    Article  PubMed  CAS  Google Scholar 

  7. J.R. Murphy, R.C. Emmott, L.L. Hicks and P.C. Walsh, Estrogen Receptors in the Human Prostate, Seminal Vesicle, Testes and Genital Skin: A Marker for Estrogen — Responsive Tissues? J. Clin. Endocrinol. and Metab. 50:938 (1980).

    Article  CAS  Google Scholar 

  8. T.T. Kiang and B.J. Kennedy, Tamoxifen (Antioestrogen) Therapy in Advanced Breast Cancer, Ann. Intern. Med. 87:687 (1977).

    Article  PubMed  CAS  Google Scholar 

  9. S. Legha and F.M. Muggia, Antiestrogens in the Treatment of Cancer, Ann. Intern. Med. 84:751 (1976).

    Article  PubMed  CAS  Google Scholar 

  10. R.C. Heel, R.C. Brogden, T.M. Speight and G.S. Avery, Tamoxifen; A Review of its Pharmacological Properties and Their Therapeutic Use in the Treatment of Breast Cancer, Drugs. 16:1 (1968).

    Article  Google Scholar 

  11. M.M. Ip, R.J. Milholland and F. Rosen, Functionality of Estrogen Receptor and Tamoxifen Treatment of R3327 Dunning Rat Prostate Adenocarcinoma, Cancer Res. 40:2188 (1980).

    PubMed  CAS  Google Scholar 

  12. F. Comhaire, Hormone Effect of an Antioestrogen, Tamoxifen, in Normal and Oligospermic Men, Fertility and Sterility, 29:320 (1978).

    PubMed  Google Scholar 

  13. F.K. Habib, G. Rafat, M.R.G. Robinson and S.R. Stitch, Effects of Tamoxifen on the Binding and Metabolism of Testosterone by Human Prostatic Tissue and Plasma in Vitro, J. Endocrinol. 83:369 (1979).

    Article  PubMed  CAS  Google Scholar 

  14. J.L. Williams, Personal Communication (1980).

    Google Scholar 

  15. L.R. Morgan, L.E. Posey and J. Lanasa, Therapeutic Use of Nolvadex (Tamoxifen ICI 46, 4741) in Advanced Prostatic Cancer, Proc. of 12. Int. Cancer Congress, Beunos Aires, 5–11 October 1978, W51 page 111, Abstract 17.

    Google Scholar 

  16. J.H. Glick, A. Wein, K. Padavic, W. Negendamk, D. Harris and H. Brodovsky, Tamoxifen in Refractory Metastatic Carcinoma of the Prostate, Cancer Treat. Rep. 64:813 (1980).

    PubMed  CAS  Google Scholar 

  17. W.B. Pratt and R.W. Ruddon, “The Anticancer Drugs, Oxford University Press, (1979) p. 212.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Springer Science+Business Media New York

About this chapter

Cite this chapter

Robinson, M.R.G. (1983). Nolvadex (Tamoxifen) an Antioestrogen of Potential Use in the Management of Carcinoma of the Prostate. In: Pavone-Macaluso, M., Smith, P.H. (eds) Cancer of the Prostate and Kidney. NATO Advanced Science Institutes Series, vol 53. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4349-3_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-4349-3_42

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-4351-6

  • Online ISBN: 978-1-4684-4349-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics